Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

In the fight against leukemia, even the most advanced treatments carry a significant risk of the disease returning. Now, Chinese scientists have developed a kind of "double-sided tape" that helps the ...

New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high ...

Chinese scientists have improved upon an existing powerful leukemia treatment, which now works even when cancer cells try to ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...